Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease

Li,Shuai-Bing; Yang,Fan; Jing,Li; Ma,Juan; Jia,Ya-Dan; Dong,Shao‑Ying; Zheng,Wei-Feng; Zhao,Luo-Sha

doi:10.3892/etm.2013.1005

Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease

Authors:
- Shuai-Bing Li
- Fan Yang
- Li Jing
- Juan Ma
- Ya-Dan Jia
- Shao‑Ying Dong
- Wei-Feng Zheng
- Luo-Sha Zhao
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan 450052, P.R. China
Published online on: March 13, 2013 https://doi.org/10.3892/etm.2013.1005
Pages: 1451-1455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a recently identified and potentially useful plasma biomarker for cardiovascular diseases. However, its role in peripheral arterial disease (PAD) remains unclear. The objective of this study was to assess the independent association of Lp-PLA2 and other inflammatory markers with the reduced ankle-brachial blood pressure index (ABI), a marker of PAD. We performed a cross-sectional study in 982 individuals aged ≥40 years who were recruited from the First Affiliated Hospital of Zhengzhou University. PAD was defined as an ABI <0.9 in at least one leg. The individuals were further divided into two groups, 145 with PAD and 837 without PAD. Following adjustment for traditional cardiovascular risk factors, the odds ratios of PAD when comparing the highest to the lowest quartiles were 3.24 (95% CI, 1.68-3.94) for Lp-PLA2, 2.14 (95% CI, 1.07‑3.11) for homocysteine, 1.93 (95% CI, 1.02‑4.01) for fibrinogen, 2.26 (95% CI, 1.32‑5.74) for apolipoprotein B and 1.3 (95% CI, 0.75‑2.49) for high-sensitivity C-reactive protein (hsCRP). When Lp-PLA2 and inflammatory markers were simultaneously included in the full model, the corresponding odds ratios were 1.81 (95% CI, 1.14‑3.68) for Lp-PLA2, 1.15 (95% CI, 0.49-2.69) for homocysteine, 1.21 (95% CI, 0.88‑5.57) for fibrinogen, 0.98 (95% CI, 0.51‑3.85) for apolipoprotein B and 1.23 (95% CI, 1.12-3.51) for hsCRP. Lp-PLA2 levels were significantly and independently associated with PAD following adjustment for other inflammatory markers. These findings reflect the potential role of circulating Lp-PLA2 as a marker of atherosclerosis.

View Figures

View References

1.	Murabito JM, Evans JC, Larson MG, Nieto K, Levy D and Wilson PW: The anklebrachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 163:1939–1942. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 344:1608–1621. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Belch JJ, Topol EJ, Agnelli G, et al: Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 163:884–892. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar
5.	Ridker PM, Stampfer MJ and Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictorsof peripheral arterial disease. JAMA. 285:2481–85. 2001. View Article : Google Scholar
6.	McDermott MM, Green D, Greenland P, et al: Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 92:194–199. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Kolodgie FD, Burke AP, Skorija KS, et al: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 26:2523–2529. 2006. View Article : Google Scholar
8.	Mannheim D, Herrmann J, Versari D, et al: Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 39:1448–1455. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Rader DJ: Inflammatory markers of coronary risk. N Engl J Med. 343:1179–1182. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Karasawa K, Harada A, Satoh N, Inoue K and Setaka M: Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res. 42:93–114. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Tsimikas S, Tsironis LD and Tselepis AD: New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 27:2094–2099. 2007. View Article : Google Scholar : PubMed/NCBI
12.	McConnell JP and Hoefner DM: Lipoprotein-associated phospholipase A2. Clin Lab Med. 26:679–697. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Sudhir K: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 90:3100–3105. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Quigley FG, Faris IB and Duncan HJ: A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes. Clin Physiol. 11:21–25. 1991. View Article : Google Scholar : PubMed/NCBI
15.	Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J and Smit AJ: ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol. 22:391–398. 1996. View Article : Google Scholar : PubMed/NCBI
16.	Carter SA: The role of pressure measurements in vascular disease. Non-Invasive Diagnostic Techniques in Vascular Disease. Bernstein EF: Mosby; Missouri: pp. 513–544. 1985
17.	Yao IST: Pressure measurement in the extremity. Vascular Diagnosis. Bernstein EF: 4th edition. Mosby; Missouri: pp. 169–175. 1993
18.	Fowkes FG: The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 17:248–154. 1988. View Article : Google Scholar : PubMed/NCBI
19.	Hirsch AT, Haskal ZJ, Hertzer NR, et al: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic). Circulation. 113:e463–e654. 2006. View Article : Google Scholar
20.	The Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 375:1536–1544. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Gong HP, Du YM, Zhong LN, Dong ZQ, Wang X, Mao YJ and Lu QH: Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis. 10:132011. View Article : Google Scholar : PubMed/NCBI
22.	Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G and Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 109:837–842. 2004. View Article : Google Scholar
23.	Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG and Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease and major adverse events at follow-up. Eur Heart J. 26:137–144. 2005. View Article : Google Scholar
24.	Stafforini DM, Tjoelker LW, McCormick SP, et al: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 274:7018–7024. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Alberti KG, Zimmet P, Shaw J, et al: The metabolic syndrome - a new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Kume N and Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 93:907–911. 1994. View Article : Google Scholar
27.	Tselepis AD and John Chapman M: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 3:57–68. 2002. View Article : Google Scholar
28.	Páramo JA, Beloqui O, Roncal C, Benito A and Orbe J: Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica. 89:1226–1231. 2004.PubMed/NCBI
29.	Nasir K, Guallar E, Navas-Acien A, Criqui Mh and Lima JA: Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999–2002. Arterioscler Thromb Vasc Biol. 25:1966–1971. 2005.